COMMUNIQUÉS West-GlobeNewswire

Intensity Therapeutics to Present Data on Intratumoral Injection of INT230-6 at the Frontiers in Cancer Immunotherapy Symposium
14/05/2019
WESTPORT, Conn., May 14, 2019 (GLOBE NEWSWIRE) -- Intensity Therapeutics, Inc. , a clinical-stage biotechnology company pioneering a novel, immune-based approach to treat solid tumor cancers through direct injection of [...]
ProMIS Neurosciences Announces First Quarter 2019 Results
14/05/2019
Company continues to show significant progress on developing highly selective antibodies targeting root cause of Alzheimer’s and Parkinson’s diseases and ALS TORONTO and CAMBRIDGE, Mass., May 14, 2019 (GLOBE NEWSWIRE [...]
Entasis Therapeutics Reports First Quarter 2019 Financial Results and Provides Business Update
14/05/2019
Transformative start to the year with the first Phase 3 trial underway and key additions to the leadership team WALTHAM, Mass., May 14, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a [...]
Myovant Sciences Announces Positive Phase 3 Results from LIBERTY 1 Study Evaluating Once Daily Relugolix Combination Therapy in Women with Uterine Fibroids
14/05/2019
- Phase 3 study met primary efficacy endpoint with highly statistically significant 73.4% response rate (p < 0.0001); women experienced, on average, an 84.3% reduction in menstrual blood loss - Achieved six key [...]
OpGen Completes Initial FDA 510(k) Submission for its Acuitas® AMR Gene Panel Test to Identify Presence of Antibiotic Resistance
14/05/2019
New molecular test designed to detect 47 antibiotic-resistance genes with high sensitivity and specificity in less than three hours, empowering healthcare facilities to make more informed infection control decisions [...]
Onconova Therapeutics, Inc. Reports Business Highlights and First Quarter 2019 Financial Results
14/05/2019
NEWTOWN, Pa., May 14, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) , a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat [...]
Myriad Genetics to Present Multiple Studies at the 2019 American Society of Clinical Oncology Annual Meeting
14/05/2019
SALT LAKE CITY, May 14, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that it will present results from multiple studies at the 2019 American Society [...]
Cronos Group and MediPharm Labs Enter $30 Million Multi-Year Private Label Cannabis Concentrate Supply Agreement with Potential to Increase to $60 Million
14/05/2019
Cronos Group and MediPharm Labs Enter Additional Multi-Year Tolling Arrangement TORONTO, May 14, 2019 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSXV: LABS) (OTCQX: MEDIF) (“MediPharm Labs”) a leader in specialized, [...]
InspireMD Announces First Quarter 2019 Financial Results
14/05/2019
On-Track to Submit U.S. IDE expected in Mid-2019 Company to Host Investor Conference Call at 8:00am ET TEL AVIV, Israel, May 14, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ [...]
Cronos Group and MediPharm Labs Enter Cannabis Concentrate Supply Agreement
14/05/2019
Cronos Group and MediPharm Labs Enter Additional Multi-Year Tolling Arrangement TORONTO, May 14, 2019 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“ Cronos Group ” or the “ Company ”), is pleased to [...]
Emerald Health Therapeutics étend la distribution de cannabis pour adultes à d'autres provinces
14/05/2019
VANCOUVER, Colombie-Britannique, 14 mai 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (« Emerald ») (TSXV: EMH; OTCQX: EMHTF) a été autorisée par PEI Cannabis et Manitoba Liquor & Lotteries Corporation [...]
OraSure Technologies to Hold Virtual Annual Meeting of Stockholders on May 21, 2019
14/05/2019
BETHLEHEM, Pa., May 14, 2019 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), announced that its 2019 Annual Meeting of Stockholders will be a completely virtual meeting, conducted as a live webcast [...]
Merus annonce le traitement d'un premier patient en phase 1 de l'essai clinique de MCLA‑145 pour des tumeurs solides avancées
14/05/2019
UTRECHT, Pays‑Bas, 14 mai 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS), une entreprise d'immuno‑oncologie de stade clinique élaborant actuellement Biclonics®, des traitements innovants à base d'anticorps [...]
Zealand Pharma achieves primary and all key secondary endpoints in confirmatory Phase 3 trial with dasiglucagon for severe hypoglycemia
14/05/2019
Company announcement – No. 15 / 2019 Zealand Pharma achieves primary and all key secondary endpoints in confirmatory Phase 3 trial with dasiglucagon for severe hypoglycemia Primary and all key secondary endpoints [...]
Rutherford Diagnostics and Philips agree 10 year partnership to improve diagnostic services and patient outcomes across England
14/05/2019
May 14, 2019 Partnership to utilize innovative technology to increase access to diagnostic services with five new community sites across England Agreement aims to deliver first class, patient-centered diagnostic [...]
GN Store Nord A/S utilises attractive market conditions and launches refinancing of convertible bond, consisting of Bond with Warrant Units
14/05/2019
NOT FOR DISTRIBUTION OR RELEASE IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ITALY, OR ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW. [...]
Aino Health AB (publ): Aino Health interim report January-March 2019
14/05/2019
14 May 2019 Aino Health interim report January-March 2019 - Large deal with client in Finland, improved profit, net sales, and cash flow, the business model is showing results. January-March 2019 · Net sales increased [...]
GENFIT: Positive 36-month DSMB Recommendation for Continuation of Phase 3 RESOLVE-IT Study of Elafibranor in NASH
14/05/2019
GENFIT: Positive 36-month DSMB Recommendation for Continuation of Phase 3 RESOLVE-IT Study of Elafibranor in NASH Data Safety Monitoring Board (DSMB) recommends the continuation of the RESOLVE-IT clinical trial without [...]
GENFIT : Issue positive du DSMB à 36 mois, recommandant la poursuite de l’étude clinique de Phase 3 RESOLVE-IT évaluant elafibranor dans la NASH
14/05/2019
GENFIT : Issue positive du DSMB à 36 mois, recommandant la poursuite de l’étude clinique de Phase 3 RESOLVE-IT évaluant elafibranor dans la NASH Le Data Safety Monitoring Board (DSMB) a recommandé la poursuite de l’ [...]

Pages